Synlogic to Study SYNB1891 With Roche's Tecentriq in Advanced Solid Tumors
May 22 2019 - 8:19AM
Dow Jones News
By Colin Kellaher
Synlogic Inc. (SYBX) on Wednesday said it plans to study its
SYNB1891 Synthetic Biotic medicine in combination with Roche
Holding AG's (ROG.EB) cancer immunotherapy Tecentriq in patients
with advanced solid tumors under a collaboration with the Swiss
drugmaker.
Synlogic, a Cambridge, Mass., clinical-stage biopharmaceutical
company, said it expects to file an investigational new drug
application with the U.S. Federal Drug Administration to begin an
open-label Phase 1 clinical trial evaluating SYNB1891 as a
monotherapy and a combination treatment with Tecentriq.
Synlogic said it will sponsor the study, while Roche will
provide the clinical supply of Tecentriq.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 22, 2019 08:04 ET (12:04 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
